Immunovaccine Inc. Named "Best Early-Stage Vaccine Biotech" at the 5th Vaccine Industry Excellence (ViE) Awards

Award Presented During the World Vaccine Congress Washington 2012

HALIFAX, NOVA SCOTIA -- (Marketwire) -- 04/13/12 -- Immunovaccine Inc. (TSX VENTURE: IMV), a clinical stage vaccine development company focused on advancing its patented DepoVax™ vaccine adjuvanting platform and product candidates for cancer therapy and infectious diseases, announced it was selected as the "Best Early-Stage Vaccine Biotech" at the 5th Vaccine Industry Excellence (ViE) Awards ceremony during the World Vaccine Congress Washington 2012 in Washington, D.C.

The annual ViE Awards honor the efforts, accomplishments and positive contributions of companies and individuals within the vaccine industry. The "Best Early-Stage Vaccine Biotech" was awarded to Immunovaccine based on the Company's strong early clinical trial results in immunotherapy and key collaborations that have expanded its product pipeline in infectious diseases, addiction and biodefense vaccines.

"It is an honor to receive this award on behalf of Immunovaccine's management team, board of directors and shareholders and is a direct result of the accomplishments and the significant contributions this team has made over the past year," said John Trizzino, CEO of Immunovaccine. "I am delighted to lead a team whose achievements have resulted in positive recognition from our peers."

About World Vaccine Congress and the ViE Awards

The World Vaccine Congress is the leading vaccine industry event for major vaccine players and is the largest and longest-running industry conference in North America. It is a place where the ever-changing dynamics of the vaccine industry are discussed and acted upon by the industry's most senior figures. The ViE awards have been created to honor and generate recognition of the efforts, accomplishments, and positive contributions of companies and individuals in the vaccine industry.

About Immunovaccine

Immunovaccine Inc. develops vaccines formulated in its DepoVax™ vaccine adjuvanting platform for cancer therapy and infectious diseases. The Company has taken its patented platform technology and proprietary cancer vaccine into Phase I human trials and has demonstrated its safety and immunogenicity potential. Immunovaccine is also capitalizing on the broad potential of its delivery platform by creating new DepoVax™-based vaccines through multiple development collaborations. In addition to the Company's human health vaccine strategy, it continues to capture value from animal health vaccine applications. Pfizer Animal Health has licensed the Company's delivery technology platform to develop vaccines for livestock. or

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Immunovaccine Inc.
John Trizzino
(902) 492-1819

Tiberend Strategic Advisors, Inc.
Andrew Mielach
(212) 827-0020

Source: Immunovaccine Inc.